Allos Therapeutics Appoints William R. Ringo to Its Board of Directors
08 1월 2007 - 9:05PM
PR Newswire (US)
WESTMINSTER, Colo., Jan. 8 /PRNewswire-FirstCall/ -- Allos
Therapeutics, Inc. (NASDAQ:ALTH) today announced that William R.
Ringo, former President and CEO of Abgenix Inc., has been appointed
to the Company's Board of Directors. "We are extremely pleased to
welcome Bill to our Board of Directors," said Paul L. Berns,
President and CEO of Allos. "Bill brings over 30 years of
experience in the pharmaceutical and biotechnology industries. We
believe his substantial leadership and commercial operating
experience will be vitally important as Allos continues to grow."
Most recently, Mr. Ringo served as President and CEO of Abgenix,
Inc. from August 2004 until April 2006, when it was acquired by
Amgen, Inc. for $2.7 billion. From June 2003 to September 2003, he
served as interim CEO of InterMune, Inc., where he continues to
serve as non-executive Chairman of the Board. Before InterMune, Mr.
Ringo spent 18 years with Eli Lilly & Company, where he served
in various senior management capacities including Product Group
President, Oncology and Critical Care Products from June 1999 until
his retirement in February 2001; President of Internal Medicine
Products from January 1998 until June 1999; and President of Eli
Lilly's Infectious Disease Business Unit from September 1995 until
January 1998. Mr. Ringo is a member of the Board of Directors of
InterMune, Inc. and Inspire Pharmaceuticals Inc. Mr. Ringo received
a B.S. in management and an M.B.A. from the University of Dayton.
About Allos Therapeutics, Inc. Allos Therapeutics, Inc. (ALTH) is a
biopharmaceutical company focused on the development and
commercialization of small molecule therapeutics for the treatment
of cancer. The Company has two product candidates in late-stage
clinical development: EFAPROXYN(TM) (efaproxiral), a radiation
sensitizer currently under evaluation in a pivotal Phase 3 trial in
women with brain metastases originating from breast cancer, and PDX
(pralatrexate), a novel, next generation antifolate currently under
evaluation in a pivotal Phase 2 trial in patients with relapsed or
refractory peripheral T-cell lymphoma. The Company is also
evaluating RH1, a targeted chemotherapeutic agent, in a Phase 1
trial in patients with advanced solid tumors. For additional
information, please visit the Company's website at
http://www.allos.com/. Note: EFAPROXYN(TM) and the Allos logo are
trademarks of Allos Therapeutics, Inc. DATASOURCE: Allos
Therapeutics, Inc. CONTACT: Jennifer Neiman, Manager, Corporate
Communications of Allos Therapeutics, +1-720-540-5227, Web site:
http://www.allos.com/
Copyright
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024
Allos Therapeutics, Inc. (MM) (나스닥)의 실시간 뉴스: 최근 기사 0
More Allos Therapeutics (MM) News Articles